BR112023022655A2 - POLARITY AND SPECIFICITY OF T LYMPHOCYTE RESPONSES SPECIFIC TO SARS-COV-2 AS A BIOMARKER OF SUSCEPTIBILITY TO THE DISEASE - Google Patents

POLARITY AND SPECIFICITY OF T LYMPHOCYTE RESPONSES SPECIFIC TO SARS-COV-2 AS A BIOMARKER OF SUSCEPTIBILITY TO THE DISEASE

Info

Publication number
BR112023022655A2
BR112023022655A2 BR112023022655A BR112023022655A BR112023022655A2 BR 112023022655 A2 BR112023022655 A2 BR 112023022655A2 BR 112023022655 A BR112023022655 A BR 112023022655A BR 112023022655 A BR112023022655 A BR 112023022655A BR 112023022655 A2 BR112023022655 A2 BR 112023022655A2
Authority
BR
Brazil
Prior art keywords
cov
sars
biomarker
specificity
polarity
Prior art date
Application number
BR112023022655A
Other languages
Portuguese (pt)
Inventor
De Sousa Eric
Jean-Eudes Fahrner
Joana Lerias
Laurence Zitvogel
Markus Maeurer
Original Assignee
Fund D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud filed Critical Fund D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud
Publication of BR112023022655A2 publication Critical patent/BR112023022655A2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

polaridade e especificidade de respostas de linfócitos t específicos para sars-cov-2 como um biomarcador de suscetibilidade à doença. o pedido refere-se a biomarcadores para avaliar se um indivíduo tem probabilidade de resistir a uma infecção por um vírus sars-cov-2 ou é susceptível ao sars-cov-2.polarity and specificity of sars-cov-2-specific t lymphocyte responses as a biomarker of disease susceptibility. The application concerns biomarkers to assess whether an individual is likely to resist infection with a Sars-Cov-2 virus or is susceptible to Sars-Cov-2.

BR112023022655A 2021-04-29 2022-04-29 POLARITY AND SPECIFICITY OF T LYMPHOCYTE RESPONSES SPECIFIC TO SARS-COV-2 AS A BIOMARKER OF SUSCEPTIBILITY TO THE DISEASE BR112023022655A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21171380 2021-04-29
EP21171378 2021-04-29
EP21306369 2021-09-30
PCT/EP2022/061635 WO2022229461A1 (en) 2021-04-29 2022-04-29 The polarity and specificity of sars-cov2 -specific t lymphocyte responses as a biomarker of disease susceptibility

Publications (1)

Publication Number Publication Date
BR112023022655A2 true BR112023022655A2 (en) 2024-04-30

Family

ID=81854483

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022655A BR112023022655A2 (en) 2021-04-29 2022-04-29 POLARITY AND SPECIFICITY OF T LYMPHOCYTE RESPONSES SPECIFIC TO SARS-COV-2 AS A BIOMARKER OF SUSCEPTIBILITY TO THE DISEASE

Country Status (6)

Country Link
EP (1) EP4330674A1 (en)
AU (1) AU2022266083A1 (en)
BR (1) BR112023022655A2 (en)
CA (1) CA3217132A1 (en)
IL (1) IL308102A (en)
WO (1) WO2022229461A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018202864A1 (en) 2017-05-05 2018-11-08 bioMérieux Method for detecting an immune cellular response

Also Published As

Publication number Publication date
CA3217132A1 (en) 2022-11-03
IL308102A (en) 2023-12-01
WO2022229461A1 (en) 2022-11-03
AU2022266083A1 (en) 2023-12-14
EP4330674A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
BR112022017930A2 (en) ANTICORONAVIRUS ANTIBODIES AND METHODS OF USE
BR112014007214A2 (en) prediction of cardiovascular risk event and its use
ECSP18081954A (en) DETECTION OF MICROBIAL INFECTION IN WOUNDS
PE20191359A1 (en) USE OF BIOMARKERS IN THE IDENTIFICATION OF PATIENTS WITH CANCER WHO WILL BE SENSITIVE TO TREATMENT WITH A PRMT5 INHIBITOR
BR112015015287A2 (en) ph formulation and indicating device
BR112012026239A2 (en) isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifying an agent capable of inhibiting the kinase activity of a resistant mutant to alk or alk fusion protein
BR112014018331A8 (en) BIOMARKERS AND COMBINED THERAPIES USING ONCOLYTIC VIRUSES AND IMMUNOMODULATION
BR112022018769A2 (en) RAPID DETECTION OF THE SARS-COV-2 VIRUS IMPLEMENTABLE IN THE FIELD
CO2019002607A2 (en) Biomarkers of metabolites for diseases associated with the contact activation system
BR112015008042A2 (en) complementary diagnoses for tec family kinase inhibitor therapy
BR112022019764A2 (en) SARS-COV-2 DETECTION TESTS
BR112018013327A2 (en) Application of Rimycin in Anti-tuberculosis Mycobacterium Infection
BR112022007996A2 (en) METHODS FOR THE TREATMENT AND USE OF BIOMARKERS TO PREDICT CLINICAL SENSITIVITY TO 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-IL)-1-OXOISOINDOLIN-5-IL)METHYL) -2,2-DIFLUOROACETAMIDE
BR112023022655A2 (en) POLARITY AND SPECIFICITY OF T LYMPHOCYTE RESPONSES SPECIFIC TO SARS-COV-2 AS A BIOMARKER OF SUSCEPTIBILITY TO THE DISEASE
BR112017006315A2 (en) therapeutic agent, use of a therapeutic agent, in vitro methods for determining whether a subject with melanoma has a higher risk of metastasis, determining a treatment regimen for a subject suffering from melanoma, treating a subject suffering from melanoma, in vitro test to predict increased risk of metastasis and kits
BR112017022320A2 (en) Methods for Lung Cancer Treatment
BR112014031957A2 (en) bag3 as biochemical serum and tissue marker
BR112022007386A2 (en) METHODS TO TREAT HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-IL)-4-((2-FLUORO-4-((3-MORPOLINOAZETIDIN-1-YL)METHYL)BENZYL )AMINO)ISOINDOLINE-1,3-DIONE
BR112021018823A2 (en) Signature for diagnosis of bacterial vs viral infections
BR112016023170A2 (en) biomarkers for hiv assessment
BR112017004883A2 (en) rgma fragment-based diagnostic assay
BR112019001446A2 (en) rna edition as biomarkers for mood disorder test
BR112016017901A2 (en) groundbreaking assay to detect human periostin
BR112017017494A2 (en) immobilized protease with improved resistance to change in the external environment
BR112022014535A2 (en) VIRUS DETECTION